CURE Strengthens Board of Directors with two new additions
Matthew Gephardt, The Gephardt Group and Bill Wernecke, Delta Air Lines Join Stellar Board
CURE Childhood Cancer, which funds breakthrough research to find a cure for pediatric cancer, while providing comprehensive support to patients, families and the provider communities that support them, today announced the appointment of two exceptional executives to its Board of Directors. Matthew Gephardt, COO and Managing Director of The Gephardt Group and Bill Wernecke, Managing Director- Charter Sales and Operations, Delta Airlines will join a strong board focused on achieving the organization’s mission of curing pediatric cancer.
“We are thrilled that Bill and Matt have agreed to lend their considerable talents, relationships and leadership to help CURE advance our mission to find cures and treatment options for pediatric cancer,” said Kristin Connor, Executive Director, CURE Childhood Cancer. “Their diverse backgrounds will further strengthen our ability to impact patients and families.”
As the COO of The Gephardt Group, Matt utilizes his diverse experience to manage all the operations, finance and corporate strategy for the company. This includes leading the firm’s labor advisory practice and doing work for major companies such as Ford Motor Company, Alcan, Boeing, and GE Aviation. Gephardt’s connection to CURE is personal; at age 17 he was diagnosed with Rhabdomyosarcoma on his prostate and bladder and was treated by Dr. Abdel Ragab, founder of CURE.
“Almost 40 years ago, the founder of CURE gave me my life back so there is no better way to honor that gift than to dedicate my efforts and service to this organization” added Gephardt. “There’s still a lot of work to be done to ensure we fund the important life-saving and hope-giving work that will make a difference for children suffering from cancer.”
In his role at Delta, Bill is responsible for all aspects of Delta’s $250+ million charter business, including sales, contracting, scheduling, planning, operations, finance, quality assurance, federal compliance and customer relationship management.
Wernecke noted, “The CURE team has done a remarkable job of raising funds to support breakthrough research while still providing care that makes a difference to patients and families. I’m excited to roll up my sleeves and get involved with helping to achieve CURE’s mission of eliminating pediatric cancer.”